Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.57 |
| ▸ | BTK | Q06187 | 9/20 | 0.53 |
| ▸ | ITK | Q08881 | 3/20 | 0.49 |
| ▸ | PLCG1 | P19174 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | BLK | P51451 | 1/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24150173 | 0.90 | JAK3 (0.56) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL30190830 | 0.88 | JAK3 (0.54) | JAK3BTKITKPLCG1EGFR | |
| SCHEMBL24150184 | 0.88 | JAK3 (0.54) | JAK3BTKITKPLCG1EGFR | |
| SCHEMBL24151339 | 0.85 | JAK3 (0.48) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL24151675 | 0.85 | JAK3 (0.58) | JAK3BTKITKPLCG1EGFR | |
| SCHEMBL30190523 | 0.85 | JAK3 (0.58) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL30191074 | 0.85 | JAK3 (0.58) | JAK3BTKITKPLCG1EGFR | |
| SCHEMBL24150532 | 0.85 | BTK (0.69) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL24151662 | 0.85 | JAK3 (0.58) | JAK3BTKITKPLCG1JAK1 | |
| SCHEMBL24150932 | 0.84 | EGFR (0.62) | JAK3BTKITKEGFRBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | JAK3 4427/4885BTK 4194/4885ITK 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.